5-Bromo-1-(tetrahydro-2H-pyran-4-yl)-1H-indole | 954387-14-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-Bromo-1-(tetrahydro-2H-pyran-4-yl)-1H-indole
• 英文别名: 5-bromo-1-(tetrahydropyran-4-yl)-1H-indole；5-bromo-1-(oxan-4-yl)indole
• CAS: 954387-14-5
• 化学式: C₁₃H₁₄BrNO
• 分子量: 280.164
• InChiKey: XGECQVSKPZAGES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  14.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  5-Bromo-1-(tetrahydro-2H-pyran-4-yl)-1H-indole 在 tris-(dibenzylideneacetone)dipalladium(0) 、 三叔丁基膦 lithium hexamethyldisilazane 、 盐酸 、 水 、 碳酸氢钠 作用下， 以 四氢呋喃 、 正己烷 、 水 、 乙酸乙酯 为溶剂， 反应 1.0h， 以88.8%的产率得到1-(tetrahydro-2H-pyran-4-yl)-1H-indol-5-amine
  参考文献：
  名称：

  1,5 And 3,6- substituted indole compounds having NOS inhibitory activity

  摘要：

  本发明涉及一种一氧化氮合酶（NOS）的抑制剂，特别是那些选择性地抑制神经一氧化氮合酶（nNOS）而不是其他NOS同工酶。本发明的NOS抑制剂，单独或与其他药用活性剂联合使用，可用于治疗或预防诸如中风、再灌注损伤、神经退行性疾病、头部创伤、冠状动脉搭桥手术（CABG）、有或无先兆的偏头痛、伴有触痛的偏头痛、中枢性中风后疼痛（CPSP）、神经病性疼痛或慢性疼痛等病症。

  公开号：

  US20070254940A1
• 作为产物：
  描述：

  N-(4-Bromo-2-(2,2-dimethoxyethyl)phenyl)tetrahydro-2H-pyran-4-amine 在 氩 作用下， 以 甲醇盐酸 为溶剂， 反应 1.0h， 以to yield compound 88 as a pale brown solid (145 mg, 100%)的产率得到5-Bromo-1-(tetrahydro-2H-pyran-4-yl)-1H-indole
  参考文献：
  名称：

  1,5 and 3,6-substituted indole compounds having NOS inhibitory activity

  摘要：

  本发明涉及一种一氧化氮合酶（NOS）抑制剂，特别是那些能够选择性地抑制神经型一氧化氮合酶（nNOS）而不影响其他NOS同工酶。本发明的NOS抑制剂可以单独或与其他药物活性剂联合使用，用于治疗或预防中风、再灌注损伤、神经退行性疾病、头部创伤、冠状动脉搭桥术（CABG）、带和不带先兆的偏头痛、带有痛觉过敏的偏头痛、中枢后中风痛（CPSP）、神经性疼痛或慢性疼痛等症状。

  公开号：

  US07989447B2

文献信息

• [EN] 1,2,4-TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS<br/>[FR] DÉRIVÉS DE LA 1,2,4-TRIAZOLO [4,3-A] PYRIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS ALLOSTÉRIQUES POSITIFS DES RÉCEPTEURS MGLUR2
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010130422A1

  公开（公告）日：2010-11-18

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及新型三唑并[4,3-a]吡啶衍生物的公式(I)，其中所有基团如权利要求中所定义。根据本发明的化合物是代谢型谷氨酸受体亚型2（"mGluR2"）的阳性变构调节剂，对于治疗或预防与谷氨酸功能障碍相关的神经和精神疾病以及代谢型受体的mGluR2亚型参与的疾病具有用处。本发明还涉及包括这种化合物的药物组合物，用于制备这种化合物和组合物的方法，以及利用这种化合物预防或治疗与mGluR2有关的神经和精神疾病和疾病。
• 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
  申请人：Cic-Nunez Jose Maria

  公开号：US20120184527A1

  公开（公告）日：2012-07-19

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及式（I）的新型三唑并[4,3-a]吡啶衍生物，其中所有基团如权利要求所定义。根据本发明的化合物是代谢型谷氨酸受体亚型2（“mGluR2”）的正向异构调节剂，可用于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体亚型mGluR2的疾病。本发明还涉及包含这些化合物的制药组合物，制备这些化合物和组合物的方法，以及使用这些化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病的用途。
• 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
  申请人：Cid-Nunez Jose Maria

  公开号：US08946205B2

  公开（公告）日：2015-02-03

  The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

  本发明涉及一种新型三唑[4,3-a]吡啶衍生物（I式），其中所有基团如权利要求所定义。本发明的化合物是代谢性谷氨酸受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能紊乱相关的神经和精神障碍以及涉及代谢性受体的mGluR2亚型的疾病。本发明还涉及包含这种化合物的药物组合物，制备这种化合物和组合物的过程，以及使用这种化合物预防或治疗涉及mGluR2的神经和精神障碍和疾病。
• Imidazo[1,2-<i>a</i>]pyridines: Orally Active Positive Allosteric Modulators of the Metabotropic Glutamate 2 Receptor
  作者：Andrés A. Trabanco、Gary Tresadern、Gregor J. Macdonald、Juan Antonio Vega、Ana Isabel de Lucas、Encarnación Matesanz、Aránzazu García、María Lourdes Linares、Sergio A. Alonso de Diego、José Manuel Alonso、Daniel Oehlrich、Abdelah Ahnaou、Wilhelmus Drinkenburg、Claire Mackie、José Ignacio Andrés、Hilde Lavreysen、José María Cid

  DOI：10.1021/jm201561r

  日期：2012.3.22

  Advanced leads of an imidazopyridine series of positive allosteric modulators of the metabotropic glutamate 2 (mGlu2) receptor are reported. The optimization of in vitro ADMET and in vivo pharmacokinetic properties led to the identification of 27o. With good potency and selectivity for the mGlu2 receptor, 270 affected sleep-wake architecture in rats after oral treatment, which we have previously shown to be indicative of mGlu2 receptor-mediated central activity.
• 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY
  申请人：Neuraxon Inc.

  公开号：EP2010527B1

  公开（公告）日：2013-08-14